GeoVax Labs, Inc. (Nasdaq: GOVX) today commented on the U.S. government's recent procurement of additional ACAM2000 (Emergent BioSolutions) smallpox vaccine, emphasizing that the award validates the continued strategic importance of maintaining robust orthopoxvirus preparedness capabilities. The procurement underscores the government's commitment to the Strategic National Stockpile and sustaining multiple medical countermeasures against smallpox and mpox threats.
"Government procurement decisions are driven by long-term national preparedness objectives rather than short-term outbreak cycles," said David Dodd, Chairman and Chief Executive Officer of GeoVax. "Continued federal investment in orthopox preparedness reinforces the importance of resilient manufacturing capacity, diversified vaccine supply, and regulatory readiness. We believe this environment strongly supports the accelerated development of GEO-MVA through its expedited regulatory pathway and the expansion of U.S.-based MVA vaccine manufacturing."
The announcement comes amid an evolving global health security landscape marked by recurring mpox outbreaks and renewed emphasis on domestic manufacturing of critical medical countermeasures. These trends reinforce the importance of maintaining a resilient and diversified biodefense infrastructure capable of responding to both naturally occurring outbreaks and potential biological threats.
GeoVax believes the long-term policy priorities align with its GEO-MVA program, which is designed to provide a U.S.-manufactured, non-replicating MVA vaccine for mpox and smallpox. Following positive scientific advice from the European Medicines Agency, GeoVax is pursuing an expedited clinical development strategy utilizing immunobridging to an approved MVA vaccine. The pivotal Phase 3 study is scheduled to initiate in the fourth quarter of 2026 with data readout anticipated by mid-2027.
The continued emphasis on orthopox preparedness, combined with recent federal initiatives supporting domestic production of critical medical countermeasures, reinforces the strategic importance of expanding U.S.-based vaccine manufacturing capacity. GeoVax notes that the recent procurement highlights the need for diversified vaccine supply, which supports the development of additional MVA-based vaccines. For more information, visit www.geovax.com.
